National Drug Policy and Authority (Registration) Regulations

1. These Regulations may be cited as the National Drug Policy and Authority (Registration) Regulations, 2014.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

This section states a single governing proposition and does not enumerate separate elements.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. "antigen" means a substance that when introduced into the body stimulates the production of an antibody and includes toxins, bacteria, foreign blood cells, and the cells of transplanted organs;
2. "Authority" means the National Drug Authority; "batch" means a defined quantity of starting material, packaging material, or product processed in a single process or series of processes and in the case of continuous manufacture, means a defined fraction of the production, characterised by its intended homogeneity and includes lot; "batch number" means a distinctive combination of numbers or letters which specifically identifies a batch, on the labels, the batch records and the certificates of analysis of a manufactured product and includes lot number; "bulk product" means any product that completes all processing stages including the final packaging; "commitment batch" means the production batches of an active pharmaceutical ingredient or finished pharmaceutical product for which the stability studies are initiated or completed post-approval through a commitment made in a regulatory application; "diagnostic antigen" means a crude or purified fraction isolated from the microbial culture and intended for in vitro detection of an existing specific immune response or antibodies; "dosage form" means the physical form in which a product is prepared for administration to the recipient; "drug" includes a herbal medicine product which is packaged for commercial purposes; "generic product" means a drug which has the same qualitative and quantitative composition in active substances and the same pharmaceutical form as the reference drug , and whose bioequivalence with the reference drug has been demonstrated by appropriate bioavailability studies; "herbal medicine product" means a finished, labeled herbal medicine product that contain as active ingredients aerial or underground parts of plants, or other plant materials, or a combination of these, whether in the crude state or as plant preparations and which may contain conventional excipients in addition to the active ingredients and may also contain by tradition, natural organic or inorganic ingredients which are not of plant origin; "immunological product" includes vaccines, immunoglobulins and antisera and in vitro diagnostic antigens; "indication" means the intended use of the product;
3. "in-process control" means checks performed during production in order to monitor and if necessary, to adjust the process to ensure that a product conforms to its specifications and includes the control of the environment or equipment; "licensed person" means a person licensed under the Act; "manufacturer" means a person licensed to manufacture drugs or active pharmaceutical ingredients; "manufacturing process" means the transformation of starting materials into finished products including drug substances or pharmaceutical dosage forms through a single operation or a sequence of operations; "master cell seed" means a collection of aliquots of a preparation of cells, for use in the preparation of a product, distributed into containers in a single operation and processed together in a manner that ensures uniformity and processed and stored in a manner that ensures stability; "master formula" means a document or set of documents specifying the starting materials with their quantities and the packaging materials, together with a description of the procedures and precautions required to produce a specified quantity of a manufactured product as well as the processing instructions, including the in-process controls;
4. "ongoing stability study" means the study carried out by a manufacturer on production batches according to a predetermined schedule in order to monitor, confirm and extend the projected re-test period or shelf-life of the active pharmaceutical ingredient, or to confirm or extend the shelf-life of the finished pharmaceutical product;
5. "patent holder" means an owner of a patent for a particular product seeking to register the product;
6. "pharmaceutical form" means the form stating-
7. "pharmaceutical product" means any medicine intended for human use and a veterinary product administered to food-producing animals, presented in its finished dosage form or as a starting material for use in the dosage form; "primary batch" means a batch of an active pharmaceutical ingredient or finished pharmaceutical product used in a stability study, from which stability data is submitted in an application for registration for the purpose of establishing a re-test period or shelf-life; "product" means a drug or preparation for human or veterinary use or a vaccine or other immunological product; "production" means all operations involved in the preparation of a pharmaceutical product, from receipt of materials, through processing and packaging, to completion of the product; "production batch" means a batch of an active pharmaceutical ingredient or finished pharmaceutical product, manufactured at production scale by using production equipment in a production facility as specified in the application; "proprietary name" means the trade or brand name which is unique to a particular product and by which the product is generally identified and registered in the country of manufacture;
8. "reprocessing" means the reworking of all or part of a batch of a product of an unacceptable quality from a defined stage of production so that its quality may be rendered acceptable by one or more additional operations;

4 further items remain in the statutory text above.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. immunological products. (1) All products shall be registered in Uganda before sale or distribution. (2) A person who intends to manufacture, import or export a product shall, prior to the manufacture, importation or exportation of the product, apply to the Authority for registration of the product.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. other immunological products. The Authority shall maintain a register of the drug or preparation, vaccine or other immunological products registered under these Regulations, in the format specified in Schedule 1 to these Regulations.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (1) An application for registration of a product shall be made to the Authority in the prescribed Form 1 of Schedule 2 to these Regulations for human or veterinary drugs and preparations and Form 2 of Schedule 2 for vaccines and other immunological products. (2) An application for registration of a product may be made by- (a) the patent holder; (b) a licensed person; (c) the manufacturer; or (d) an agent authorised by the manufacturer or patent holder. (3) The application shall state- (a) the name, physical address, email address, the telephone and fax number of the applicant; (b) the proprietary name of the product; (c) the approved generic name of the product; (d) the particulars of the product; (e) the strength of the product in per unit form such as mg, mL, IU/G or IU/M, where applicable; (f) the indication of the intended use of the product; (g) the description of the product; (h) the packaging specifications specified in regulation 10;
2. (i) the studies undertaken in respect of the product, if any; (j) the safety and efficacy properties of the product; (k) the chemistry and pharmaceutical form and aspects of the product; (l) the registration and licensing status of the product in other countries including the country of manufacture; (m) the particulars relating to the toxicology and pharmacology of the product; and (n) any other information as may be determined by the Authority. (4) The application shall be in writing, in the English language and shall in addition to the requirements referred to under subregulation (3) be accompanied by- (a) two samples of the product; (b) all the general and specific information and documents relating to the product; (c) a complete index to the various appendices; and (d) the prescribed fees. (5) Where the original documents required under subregulation (4) are in a language other than English, the original documents shall be presented together with certified English translations. (6) Where an applicant wishes to amend any part of a submitted application, the applicant shall pay the prescribed fees for each proposed amendment.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (1) Where the applicant is not the manufacturer of the product, the applicant shall provide in relation to the manufacturer- (a) the name, physical address, email address, telephone and fax number of the manufacturer; and (b) a copy of the manufacturing licence. (2) Where different activities of manufacturing are carried out at more than one site, the applicant shall provide the particulars specified in subregulation (1) in respect of each site, clearly specifying the activity which is carried out at each site.
2. (3) The applicant shall provide details of-
3. (a) the procedures used at the various stages of manufacture in the form of a flow diagram accompanied by a list of the equipment used at each stage; and
4. (b) the analytical, microbiological and other process control procedures and the frequency and sequence in which they are carried out during the manufacturing process.
5. (4) The applicant shall provide the characteristics of a manufactured product by- (a) stating the details of the product including- (i) the name, dosage form and strength of the product; (ii) the approved generic name of the product, if any; (iii) the visual description of the manufactured product; and (iv) the visual description of the packaging for the product; and (b) stating the regulatory status of the product in other countries including the country of origin.
6. (5) In addition to the requirements under subregulation (4), the application shall also contain the details of the active pharmaceutical ingredient including- (a) the nomenclature of the active pharmaceutical ingredients; (b) the properties of the active pharmaceutical ingredients used; (c) the site of manufacture for the active pharmaceutical ingredients; (d) the route of synthesis of the active pharmaceutical ingredients used; (e) the specifications of the active pharmaceutical ingredients bearing the justification for such specifications; (f) the container closure system including the description and identification of the components; and (g) the results of the stability testing. (6) An applicant for registration of a manufactured product shall in the application furnish the Authority with the following-
7. (a) a valid licence or other form of authorisation for manufacturing the product;
8. (b) the pharmaceutical development detailing the studies conducted in relation to the product;

13 further items remain in the statutory text above.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. their analytical methods (1) The applicant shall provide the specifications of the raw material to be used and details of the analytical methods used for the raw materials. (2) Where World Health Organisation Technical Report Series or pharmacopoeial references to specifications and analytical methods are given, photocopies of the references or monographs shall be supplied. (3) For non World Health Organisation Technical Report Series, nonpharmacopoeial raw materials, the following information shall be provided- (a) a description of the active immunogenic raw materials; (b) the pysico-chemical tests conducted; (c) the biological activity tests conducted; (d) comprehensive details of the procedures involved in the various stages of the manufacture of the products; (e) summarised specifications of the manufactured products including the acceptable limits of all the physical and other control procedures carried out to ascertain the specifications of the final product; (f) the specifications and test methods for all dosage forms; (g) the batch manufacturing records; (h) stability studies on the manufactured products; and (i) test samples.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (1) The applicant shall state the details of the manufacturer of the active raw material and the description of the methods of manufacture of the active raw material.
2. (2) The description referred to under subregulation (1) shall include-
3. (a) a description of the source of the raw material and the specifications and the test methods of the starting materials such as- (i) the animal sources; (ii) the virus sources;
4. (iii) the cellular sources including microbial cells, animal cells, primary cells, and cell lines;
5. (iv) the genetic constructs and recombinant cell lines including host cells, gene construct, vector, final gene construct and cloning and establishment of recombinant cell lines; and
6. (v) the cell bank system including master cell bank, working cell bank, end of production cells and characterisation and testing of cell banks;
7. (b) a description of the growth and harvesting process including propagation and harvesting;
8. (c) the purification and downstream processing including inactivation, where appropriate, purification, where appropriate, stability processing and detoxification;

2 further items remain in the statutory text above.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (1) The applicant shall at the time of applying for registration of a product provide a sample of the labelling and packaging for the product which shall contain- (a) the brand name, where applicable; (b) the international non-proprietary name or generic name of the product; (c) the quantity of active ingredient per dosage unit;
2. (d) the pharmaceutical form and the quantity of active ingredient per dosage unit; (e) the total contents of the primary, secondary and tertiary container; (f) the date of manufacture of the product; (g) the date of expiry of the product; (h) the batch number of the product; (i) the storage conditions;
3. (j) the product information for health professionals; (k) the patient information and package leaflet; and (l) the name and address of the manufacturer of the product.
4. (2) The Authority shall not consider an application for registration of a product unless the words used in the labelling and packaging of the product are in English.
5. (3) The name and address of the manufacturer, the date of manufacture or the conditions of storage may be omitted from the primary packaging if the primary packaging is a blister, strip pack or a vial or an ampoule of less than ten millilitres.
6. (4) The name of the manufacturer may be substituted with a trade mark or other symbol associated with the manufacturer.
7. (5) Where the name and address of the manufacturer, the date of manufacture or the conditions of storage are omitted from the primary packaging under subregulation (3), they shall appear in full on the secondary packaging.
8. (6) The application shall also contain- (a) justification for any differences to the product in the country issuing the submitted World Health Organisation Type Certificate such as a certificate issued in terms of the World Health Organisation Certification Scheme for Pharmaceutical Products Moving in International Commerce or the Certificate of a Pharmaceutical Product;

3 further items remain in the statutory text above.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (a) the proposed therapeutic use of the product;
2. (b) the evidence of the potential benefit of using the product in Uganda; and
3. (c) the potential side effects of the product.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (1) The product packaging shall include a prescribing information leaflet in the case of prescription medicines or a patient information leaflet in the case of non-prescription medicine.
2. (2) The leaflet shall include the following information-
3. (a) the international non-proprietary or botanical name, where appropriate;
4. (b) a brief description of the mechanism of action and pharmacological effects;
5. (c) clinical information on the product including-
6. (i) not more than three indications;
7. (ii) the dosage regimens for the different age groups, including for children;
8. (iii) the contraindications; (iv) precautions in pregnancy; (v) lactation, renal and hepatic failure, if any; (vi) the adverse reactions including their frequency; (vii) clinically significant drug interactions; and (viii) the symptoms and treatment of over dosage; and

4 further items remain in the statutory text above.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (1) Where the product to be registered by the Authority is manufactured outside Uganda, the product shall be registered in the country of manufacture, prior to registration in Uganda.
2. (2) The applicant for registration of a product manufactured outside Uganda shall furnish the Authority with a certified copy of the certificate of registration issued by the country of manufacture and the conditions of registration, if any.
3. (3) Notwithstanding the requirements of this regulation, the applicant may submit a certificate of pharmaceutical product issued under the World Health Organisation Certification Scheme or any other scheme approved by the Authority, on the quality of a pharmaceutical product moving in international commerce instead of the certificate of registration.
4. (4) Where the applicant submits a certificate under subregulation (3), the exporting country shall be deemed to be the country of manufacture.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (1) The Authority shall issue a certificate of registration of a product registered under these Regulations, in the prescribed Form 3 of Schedule 3 to these Regulations.
2. (2) The Authority shall issue a certificate of registration where the Authority is satisfied that-
3. (a) the product dossier is submitted with evidence of-
4. (i) the safety, efficacy and quality of the product;
5. (ii) the stability of the data regarding the product; and
6. (iii) two samples of the drug or preparation;
7. (b) for an ectoparasiticides, a field trial, to prove the claims of efficacy of the preparation in animals and the safety of the people and environment exposed to these products, was carried out in Uganda;
8. (c) the applicant has complied with internationally accepted Good Manufacturing Practices, adopted by the Authority; and

1 further item remain in the statutory text above.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (1) The certificate of registration of a product shall be suspended for failure of the holder of the certificate of registration-
2. (a) to meet the quality specifications and standards of the registered product; or
3. (b) to renew the certificate of Good Manufacturing Practice.
4. (2) A certificate of registration a product shall be cancelled where-
5. (a) the holder of the certificate of registration fails to meet the quality specifications and standards required of the registered products;
6. (b) the holder of the certificate of registration fails to renew the certificate of Good Manufacturing Practice;
7. (c) the registered product is banned or is declared obsolete by the Authority;
8. (d) the registered product has serious adverse reactions as may be determined by the Authority;

2 further items remain in the statutory text above.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (a) a list of the active ingredients or immunogens and their amount per unit dose;
2. (b) a list of all excipients, adjuvants and preservatives, their amount per unit dose and the reason for their inclusion in the formulation; and
3. (c) details of the adverse effects of the drug or preparation to animals and precautions to be taken before or during use in certain animals.
4. (2) Where a drug or preparation has adverse effects, the drug shall not be registered.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (a) the summary of the pharmacokinetics of the drug and its residues;
2. (b) how long the drug or its metabolites persists in animal tissue;
3. (c) the practical withdrawal periods that should be observed before slaughtering the animals for consumption or consumption of other food products from live animals;
4. (d) the analytical methods suitable for verifying the appropriateness of the withdrawal period; and
5. (e) the potential of the veterinary product to cause drug resistance in human beings exposed to animal products that were treated with the veterinary drug or preparation.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (1) The applicant shall provide information relating to the assessment of the potential of exposure of the drug or preparation and its active metabolites to the environment taking into account-
2. (a) the target species and the likelihood of and method of excretion of the drug or preparation and its active metabolites into the environment;
3. (b) the pattern of use and quantity of the drug or preparation used for herd or flock medication or individual medication;
4. (c) the method of administration and whether it may lead to direct entry of the drug or preparation into the environment; and
5. (d) the method of disposal of the unused drug or preparation.
6. (2) The applicant shall provide information on the studies carried out on the potentially harmful effects of the drug or preparation to the environment and the measures proposed to minimise the risks during the use of the product including- (a) the fate and behaviour of the drug or preparation in the soil; (b) the effects of the drug or preparation on soil organisms; (c) fate and behaviour of the drug or preparation in water; (d) the effect of the drug or preparation on aquatic organisms; and (e) the effect of the drug or preparation on other non-target organisms. Additional Requirements for Herbal Medicine Products

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (1) An application for the registration of an imported herbal medicine product shall be made to the Authority, in the prescribed Form 4 for imported herbal medicine product for human use or Form 5 for imported herbal medicine product for veterinary use, as the case may be, of Schedule 4 to these Regulations.
2. (2) An application for the registration of a local herbal medicine product shall be made to the Authority in prescribed Form 6 of Schedule 4 to these Regulations.
3. (3) An application for registration under subregulation (1) or (2) shall be made by- (a) the patent holder or the owner of the formulation of the herbal medicine product;
4. (b) a licensed person; (c) the manufacturer of the herbal medicine product; or (d) an agent authorised by the manufacturer or the patent holder. (4) The application shall contain-
5. (a) the name, physical address, telephone number, fax number, and e- mail address of the applicant; (b) the name of the herbal medicine product; (c) the name of the active or main constituent of the herbal medicine product; (d) the indications of the herbal medicine product; (e) the form of preparation of the herbal medicine product, such as belladonna leaf, opium tincture, yeast tablets or convallaria tonic; (f) the dosage forms of the herbal medicine product, such as tablet, powder, ointment or capsules;
6. (g) where applicable, the strength of dosage form of the herbal medicine product;
7. (h) the excipients of the herbal medicine product, such as starch, or honey; (i) the major adverse effects of the herbal medicine product; (j) two samples of the packaging of the herbal medicine product;
8. (k) the storage conditions, shelf life and expiry date of the herbal medicine product;

16 further items remain in the statutory text above.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (a) the microbiological contamination tests and tests for other toxins, if any;
2. (b) the uniformity of weight for tablets, single-dose powders, suppositories, sachets and capsules, the disintegration time for tablets, capsules, suppositories and pills, the hardness and friability such as of uncoated tablets, the viscosity for internal and external fluids, the consistency or semisolid preparations, and dissolution tablets or capsules, if applicable;
3. (c) the physical appearance of the herbal medicine product, such as colour, odour, form, shape, size and texture;
4. (d) the loss on drying or water content of the herbal medicine product;
5. (e) identity tests and qualitative determination of the relevant substances of the plants used in the herbal medicine product including finger- print chromatograms; (f) the quantification of the relevant active ingredients of the herbal medicine product, where these are identified and where the analytical methods are adequate ; and
6. (g) limit tests for the residual solvent in the herbal medicine product.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. to herbal medicine products The requirements of good manufacturing practices shall not apply to herbal medicine products.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. The Authority shall issue a certificate of registration for a herbal medicine product in the prescribed Form 3 of Schedule 3 to these Regulations.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. A certificate of registration of a herbal medicine product shall be suspended for failure of the holder of the certificate to meet the quality specifications and standards of the registered herbal medicine product.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. "adverse event" means a problem that can or does result in permanent impairment, injury or death to the patient or the user;
2. "in vitro diagnostic device" means a surgical instrument that is intended to be used in vitro for the examination of specimens taken from the body of a human being or of an animal;
3. "significant change" means a change that could reasonably be expected to affect the safety or effectiveness of a surgical instrument;
4. "surgical instrument" means any instrument, apparatus, implement, machine, implant, in vitro reagent or calibrator, software, material or other similar or related article and includes an appliance which is intended by the manufacturer to be used, alone or in combination, for human beings or animals for one or more of the specific purposes of- (a) diagnosis, prevention, monitoring, treatment or alleviation of disease;

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (1) All surgical instruments shall be registered by the Authority before sale or distribution in Uganda.
2. (2) The Authority shall register the surgical instruments which meet the safety and efficacy standards determined by the Authority.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. The Authority shall maintain a register of the surgical instruments registered under these Regulations, in the format specified in Schedule 5 to these Regulations.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (1) A person who intends to manufacture, import or export a surgical instrument shall, prior to the manufacture, importation or exportation of the surgical instrument, apply to the Authority for registration of the surgical instrument.
2. (2) An application for registration of a surgical instrument shall be made to the Authority in the prescribed Form 7 of Schedule 6 to these Regulations.
3. (3) An application for registration of a product in Uganda may be made by-
4. (a) the patent holder;
5. (b) a licensed person;
6. (c) the manufacturer of the surgical instrument; or
7. (d) an agent authorised by the manufacturer or patent holder.
8. (4) An application shall contain-

10 further items remain in the statutory text above.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (1) Where a surgical instrument or a group of surgical instruments is registered and the instrument or group of surgical instruments, as the case may be, forms part of another surgical instrument or of another group of surgical instruments, as the case may be, all the surgical instruments or the group shall be deemed to be registered.
2. (2) Where a test kit is licensed or registered outside Uganda, all the reagents or articles of the test kit that are manufactured by the manufacturer of the test kit are deemed, for the purposes of its importation, sale or advertisement, to have been registered in Uganda.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (1) The applicant shall submit with the application for registration of a surgical instrument, a label which shall have-
2. (a) the name of the surgical instrument;
3. (b) the name and address of the manufacturer of the surgical instrument;
4. (c) the identifier of the surgical instrument, including the identifier of any surgical instrument or appliance that is part of a system, test kit or group;
5. (d) where the contents of the package of the surgical instrument are not readily apparent, an indication of what the package contains, expressed in terms appropriate to the surgical instrument, such as the size, net weight, length, volume or number of units;
6. (e) the word "Sterile", if the manufacturer intends the device to be sold in a sterile condition; (f) the expiry date of the surgical instrument, where applicable, to be determined by the manufacturer on the basis of the component of the surgical instrument, as the case may be, that has the shortest projected useful life; (g) unless self-evident to the intended user, the medical conditions, purposes and uses for which the surgical instrument is manufactured, sold or represented, including the performance specifications of the surgical instrument, where those specifications are necessary for proper use; (h) the directions for safe and effective use of the surgical instrument, unless directions are not required; and (i) any special storage conditions applicable to the surgical instrument.
7. (2) The information required under subregulation (1) shall be provided in English, and shall be in a permanent and prominent manner, in terms that are easily understood by the intended user.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (1) The Authority shall issue a certificate of registration for a surgical instrument which is registered under these Regulations. (2) The certificate of registration shall be in the prescribed Form 8 of Schedule 7 to these Regulations. (3) The Authority may set out in the certificate of registration the terms and conditions for registration including- (a) the tests to be performed on a surgical instrument to maintain the safety and efficacy requirements; and
2. (b) the requirement to submit the results of any tests performed on the surgical instrument.
3. (4) The Authority may, taking into account new development with respect to a surgical instrument, amend the terms and conditions of the registration of a surgical instrument.
4. (5) The holder of the surgical instrument certificate shall comply with the terms and conditions of the certificate of registration.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (1) The Authority may suspend the registration of a surgical instrument by giving the holder of the certificate of registration a notice of the suspension, in writing, that states the reason for the suspension. (2) The Authority shall suspend a registration where the Authority determines that- (a) the holder of the certificate of registration has contravened these Regulations or any provision of the Act; (b) the holder of the certificate of registration made a false or misleading statement in the application for registration; (c) the holder of the certificate of registration has not complied with the terms and conditions of the certificate of registration; or (d) the surgical instrument no longer meets the safety and efficacy standards determined by the Authority.
2. (3) Before suspending the registration of a surgical instrument under this regulation, the Authority shall- (a) consider the record of the holder of the certificate of registration, of compliance with the Act and these Regulations;
3. (b) consider whether maintaining the registration would cause injury to the health or safety of patients, the users of the surgical instrument or any other persons; and
4. (c) give written notice of the intention to suspend a registration to the holder of the certificate of registration, which shall set out the reason for the proposed suspension, any corrective action required to be taken to avoid the suspension and the time within which the corrective action is to be taken.
5. (4) The Authority shall not suspend the registration of a surgical instrument-
6. (a) where corrective action is required by the Authority under subregulation (3) (c) and the time which the corrective action is to be taken has not elapsed; and
7. (b) without giving the holder of the certificate of registration an opportunity to be heard by the Authority.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. of patients, users and other persons Notwithstanding regulation 31 (4) (b), the Authority may suspend the registration of a surgical instrument without giving the holder of the certificate of registration an opportunity to be heard, where it is necessary to do so to prevent injury to the health or safety of patients, users or any other persons.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. The Authority may reinstate the registration of a surgical instrument where the situation that caused the suspension is corrected or where the reason for the suspension was unfounded.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. A surgical instrument shall not, when used for the medical conditions and purpose for which it was manufactured, adversely affect the health or safety of a patient, user or any other persons.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (1) Subject to subregualtion (2), where a surgical instrument or appliance is intended to be sold to the general public, the information required under regulation 29 (1) shall- (a) be set out on the outside of the package that contains the surgical instrument or appliance; and (b) be visible under the normal conditions of sale of the surgical instrument or appliance. (2) Where the package that contains the surgical instrument or appliance is too small to display all the information required under regulation 29 on the outside of the package, the directions for the use of the surgical instrument or appliance shall accompany the surgical instrument or appliance.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. information submitted The applicant for registration under these Regulations shall be responsible for the accuracy of the information submitted in support of the application for registration and for any alterations to the information supplied.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (1) Where the information or documents submitted in respect of an application for registration or an application for amendment or alteration of a registration under these Regulations, are not sufficient for the Authority to determine whether the human or veterinary drug or preparation, vaccine or other immunological products or surgical instrument to be registered meets the safety and efficacy requirements determined by the Authority, the Authority may request the applicant to submit additional information necessary for the registration.
2. (2) In the course of examining an application, the Authority may request an applicant to provide a sample of the human or veterinary drug or preparation, vaccine or other immunological or surgical instrument to be registered.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (1) The Authority shall determine an application for registration under these Regulations, within sixty days from the date of receipt of the application.
2. (2) Where the Authority is satisfied with an application, it shall approve the application and register the human or veterinary drug or preparation, vaccine or other immunological or surgical instrument, as the case may be.
3. (3) Where the Authority is not satisfied with the information provided in an application, the Authority shall require the applicant to provide further information as may be necessary to complete the application.
4. (4) Where the Authority does not accept an application, the Authority shall communicate its decision and the reasons for refusal to the applicant.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (1) Whenever a holder of a certificate of registration wishes to make an amendment or an alteration to the particulars provided in the application for registration made under these Regulations, the holder of the certificate of registration shall apply to the Authority for amendment or alteration of the registration. (2) An application for amendment or alteration of registration shall be shall be accompanied by-
2. (a) a detailed description of the amendment or alteration to be effected with reasons for the amendment or alteration;
3. (b) where applicable, samples of the altered human or veterinary drug or preparation, vaccine or other immunological products or surgical instrument, as the case may be; and
4. (c) the prescribed fee.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (1) The Authority shall issue for the first registration, a certificate of registration which shall be valid for five years. (2) The holder of a certificate of registration issued under subregulation (1) shall pay an annual retention fee prescribed by the Authority for maintaining the registered human or veterinary drug or preparation, vaccine or other immunological products or surgical instrument, on the Register. (3) A certificate for renewal of registration shall be valid for one year from the date of issue. (4) The certificate of registration issued under these Regulations shall be kept at the premises of the holder of the certificate of registration. (5) The holder of a certificate of registration shall monitor the safety and effectiveness of the registered human or veterinary drug or preparation, vaccine or other immunological products or surgical instrument while on the market in Uganda and shall submit periodic reports as may be prescribed by the Authority. (6) The registration of a human or veterinary drug or preparation, vaccine or other immunological products or surgical instrument under these Regulations shall be valid except where the registration is suspended or cancelled by the Authority or is terminated by the holder of the certificate of registration.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (1) The Authority may refuse to issue, amend or alter a certificate of registration where- (a) the applicant does not comply with these Regulations or any provisions of the Act; (b) the human or veterinary drug or preparation, vaccine or other immunological products or surgical instrument, as the case may be, does not meet the safety and efficacy standards determined by the Authority; (c) the information or samples submitted are not sufficient to enable the Authority to determine whether the human or veterinary drug or preparation, vaccine or other immunological products or surgical instrument, as the case may be, meets those requirements and the applicant does not comply with a request to submit additional information or samples; (d) the applicant makes a false or misleading statement in the application;
2. (e) the human or veterinary drug or preparation, vaccine or other immunological products or surgical instrument, as the case may be, or its sample label does not comply with the labelling requirements specified in these Regulations. (2) Where the Authority refuses to issue, amend or alter the registration of a drug or preparation, vaccine or other immunological products or surgical instrument, as the case may be, the Authority shall- (a) notify the applicant in writing of the reasons for the refusal; and
3. (b) give the applicant an opportunity to be heard.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. (1) A holder of a certificate of registration who wishes to renew the registration shall submit an application for renewal of registration, to the Authority at least 90 days before the expiry of the registration.
2. (2) An application for renewal of registration shall be in writing to the Authority and shall be accompanied by-
3. (a) a consolidated report of the changes, if any, whether reported to the Authority or not, which are made with respect to the registered drug or preparation, vaccine or other immunological products or surgical instrument, as the case may be, during the validity of its registration;
4. (b) a report of additional adverse drug reactions, if any, detected during the lifetime of the registered drug or preparation, vaccine or other immunological products or surgical instrument, as the case may be;
5. (c) five samples of the packaging of the registered drug or preparation, vaccine or other immunological products or surgical instrument, as the case may be, for which renewal of registration is sought, in the form in which it is to be marketed; (d) the prescribed fee.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. The fees to be paid under these Regulations shall be prescribed by the Authority.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.

1. A person contravening a provision of these Regulations commits an offence and shall be liable to any of the penalties set out under the Act.

No judgment in the current Wakilii corpus expressly cites this section. Bare rule-number references are not assigned where the Order cannot be verified.